Detection of Immune Microenvironment Changes and Immune-Related Regulators in Langerhans Cell Histiocytosis Bone Metastasis
In conclusion, our study constructed an atlas of the immune microenvironment of LCH bone metastasis. Genes including LAG3, TSPAN5, LPAR5, VEGFA, CXCL16, CD74, and MARCKS may be involved in the development of LCH bone metastasis. The hub gene-immune cell interactive map may be a potential prognostic biomarker for the progression of LCH bone metastasis and synergetic targets for immunotherapy in LCH patients.PMID:36714021 | PMC:PMC9879691 | DOI:10.1155/2023/1447435 (Source: Cell Research)
Source: Cell Research - January 30, 2023 Category: Cytology Authors: Jinding Lin Haifeng Tang Zhitong Xu Rongdong Zeng Source Type: research

Detection of Immune Microenvironment Changes and Immune-Related Regulators in Langerhans Cell Histiocytosis Bone Metastasis
In conclusion, our study constructed an atlas of the immune microenvironment of LCH bone metastasis. Genes including LAG3, TSPAN5, LPAR5, VEGFA, CXCL16, CD74, and MARCKS may be involved in the development of LCH bone metastasis. The hub gene-immune cell interactive map may be a potential prognostic biomarker for the progression of LCH bone metastasis and synergetic targets for immunotherapy in LCH patients.PMID:36714021 | PMC:PMC9879691 | DOI:10.1155/2023/1447435 (Source: Biomed Res)
Source: Biomed Res - January 30, 2023 Category: Research Authors: Jinding Lin Haifeng Tang Zhitong Xu Rongdong Zeng Source Type: research

Comparison of whole-body DW-MRI with 2-[ < sup > 18 < /sup > F]FDG PET for staging and treatment monitoring of children with Langerhans cell histiocytosis
CONCLUSION: Our study showed that WB DW-MRI has similar accuracy to 2-[18F]FDG PET for staging and treatment monitoring of LCH in children. While 2-[18F]FDG PET remains an approved radiological examination for assessing metabolically active disease, WB DW-MRI could be considered as an alternative approach without radiation exposure. The combination of both modalities might have advantages over either approach alone.PMID:36717409 | DOI:10.1007/s00259-023-06122-6 (Source: Molecular Medicine)
Source: Molecular Medicine - January 30, 2023 Category: Molecular Biology Authors: Lucia Baratto Ramyashree Nyalakonda Ashok J Theruvath Amir Hossein Sarrami Kristina Elizabeth Hawk Ali Rashidi Sa Shen Lisa States Mariam Aboian Michael Jeng Heike E Daldrup-Link Source Type: research

Detection of Immune Microenvironment Changes and Immune-Related Regulators in Langerhans Cell Histiocytosis Bone Metastasis
In conclusion, our study constructed an atlas of the immune microenvironment of LCH bone metastasis. Genes including LAG3, TSPAN5, LPAR5, VEGFA, CXCL16, CD74, and MARCKS may be involved in the development of LCH bone metastasis. The hub gene-immune cell interactive map may be a potential prognostic biomarker for the progression of LCH bone metastasis and synergetic targets for immunotherapy in LCH patients.PMID:36714021 | PMC:PMC9879691 | DOI:10.1155/2023/1447435 (Source: Biomed Res)
Source: Biomed Res - January 30, 2023 Category: Research Authors: Jinding Lin Haifeng Tang Zhitong Xu Rongdong Zeng Source Type: research

Case Report of Erdheim-Chester Disease Successfully Treated with Pegylated Interferon: A Single-Center Experience
Cancer Res Treat. 2023 Jan 19. doi: 10.4143/crt.2022.1535. Online ahead of print.ABSTRACTErdheim-Chester disease (ECD), also known as non-Langerhans cell histiocytosis, is a multi-systemic disease with unclear pathogenesis. Based on a small number of case studies, pegylated interferon-alpha (PEG-IFN-α) has been used as the front-line treatment option. However, there are limited data regarding administration of ropegylated-interferon α-2b (ROPEG-IFN-α 2b) for ECD patients. Herein, we report two cases of severe ECD treated with two types of PEG-IFN-α. One patient with heart and skeleton involvement and BRAF V600E mutatio...
Source: Cell Research - January 26, 2023 Category: Cytology Authors: Yujin Lim Sang Eun Yoon Junhun Cho Darae Kim Chul Won Jung Source Type: research

Association of bilateral pan-uveitis with the use of trametinib for Langerhans cell histiocytosis
In conclusion, MEK (mitogen-activated protein/extracellular signal-related kinase kinase) inhibitor trametinib treatment alone might be associated with ocular toxicity presenting as Vogt Koyanaki Harada syndrome-like pan-uveitis. Ocular symptoms and signs should be monitored carefully during MEK inhibitor therapy.PMID:36628254 | PMC:PMC9827292 (Source: American Journal of Translational Research)
Source: American Journal of Translational Research - January 11, 2023 Category: Research Authors: Yu Du Yun-Tao Hu Source Type: research

Association of bilateral pan-uveitis with the use of trametinib for Langerhans cell histiocytosis
In conclusion, MEK (mitogen-activated protein/extracellular signal-related kinase kinase) inhibitor trametinib treatment alone might be associated with ocular toxicity presenting as Vogt Koyanaki Harada syndrome-like pan-uveitis. Ocular symptoms and signs should be monitored carefully during MEK inhibitor therapy.PMID:36628254 | PMC:PMC9827292 (Source: Cell Research)
Source: Cell Research - January 11, 2023 Category: Cytology Authors: Yu Du Yun-Tao Hu Source Type: research

Association of bilateral pan-uveitis with the use of trametinib for Langerhans cell histiocytosis
In conclusion, MEK (mitogen-activated protein/extracellular signal-related kinase kinase) inhibitor trametinib treatment alone might be associated with ocular toxicity presenting as Vogt Koyanaki Harada syndrome-like pan-uveitis. Ocular symptoms and signs should be monitored carefully during MEK inhibitor therapy.PMID:36628254 | PMC:PMC9827292 (Source: American Journal of Translational Research)
Source: American Journal of Translational Research - January 11, 2023 Category: Research Authors: Yu Du Yun-Tao Hu Source Type: research